Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19

NCT05172037 is registered in ClinicalTrials.gov with Genova Inc. as lead sponsor.

NCT NCT05172037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05172037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients With Mild COVID-19
Lead sponsor
Genova Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
October 28, 2021
Completion date
June 30, 2022
Enrollment
222 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid19